Blockade of PAR2 Signaling by Punicalagin as a Therapeutic Strategy for Atopic Dermatitis
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26188920 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Hyejin Jeon und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Kor…. Hauptthemen laut MEDLINE: Receptor, PAR-2, Dermatitis, Atopic, Hydrolyzable Tannins, Signal Transduction. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Education.
Abstract (Originalsprache)
Atopic dermatitis is a chronic inflammatory skin disorder characterized by persistent inflammation and severe pruritus. Current anti-inflammatory agents carry risks of long-term adverse effects, while antihistamines provide limited relief of pruritus. Protease-activated receptor 2 (PAR2) has emerged as a critical mediator of both inflammation and pruritus, representing a promising therapeutic target. In this study, we investigated the therapeutic potential of punicalagin (PCG), a potent PAR2 antagonist, in atopic dermatitis. PCG fully and potently inhibited trypsin-induced PAR2 activation in HaCaT cells with an IC50 of 1.30 µM, exhibiting over 40-fold greater selectivity over PAR1. PCG significantly inhibited PAR2-induced phosphorylation of ERK1/2 and NF-κB in both HaCaT and human dermal fibroblast cells and reduced IL-8 secretion in HaCaT cells. In addition, PCG did not significantly affect other pruritus-related GPCRs including H1R, H4R, TGR5, 5HT2A, 5HT2B, and MRGPRX2 at 30 µM. Notably, PCG strongly blocked PAR2-AP-induced scratching in mice. In addition, PCG improved skin lesions, reduced dermatitis severity scores, and alleviated scratching behavior in a DNFB-induced atopic dermatitis model. These effects were associated with reduced epidermal thickness, decreased serum TSLP levels, and inhibition of PAR2-dependent calcium signaling in dorsal root ganglion neurons. These findings demonstrate that PCG is a selective PAR2 antagonist that effectively alleviates both inflammatory and pruritic symptoms of atopic dermatitis, suggesting its potential as a novel therapeutic agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.
- Department of Bio-Nanomaterials, Bio Campus of Korea Polytechnics, 112 Dongan-ro, Ganggeong-up, Nonsan 32943, Republic of Korea.
- College of Pharmacy, Gachon University, 191 Hambangmoero, Yeonsu-gu, Incheon 21936, Republic of Korea.
ORCID-Profile: Hyejin Jeon, Yohan Seo, Wook-Joo Lee, Yunkyung Heo, Wan Namkung
Förderung
- National Research Foundation of Korea
- Ministry of Education
Zitieren
APA
Jeon, H., Seo, Y., Lee, W. J., Heo, Y., Shim, W. S., & Namkung, W. (2025). Blockade of PAR2 Signaling by Punicalagin as a Therapeutic Strategy for Atopic Dermatitis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26188920
Vancouver
Jeon H, Seo Y, Lee WJ, Heo Y, Shim WS, Namkung W. Blockade of PAR2 Signaling by Punicalagin as a Therapeutic Strategy for Atopic Dermatitis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26188920
BibTeX
@article{Jeon2025,
author = {Jeon, Hyejin and Seo, Yohan and Lee, Wook-Joo and Heo, Yunkyung and Shim, Won-Sik and Namkung, Wan},
title = {Blockade of PAR2 Signaling by Punicalagin as a Therapeutic Strategy for Atopic Dermatitis},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26188920}
}
EUVIMED